1. Headache Classification Committee of the International Headache Society, International Classification of Headache Disorders, 3rd ed. Cephalalgia. 2018;38(1):1-211.

2. European principles of management of common headache disorders in primary care. J Headache Pain. 2007;8(suppl 1):S1-S49.

3. Bendtsen L, Birk S, Kasch H. Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society2nd ed. J Headache Pain. 2012;13(suppl 1):S1-S29.

4. Goadsby PJ. Recent advances in the diagnosis and management of migraine. BMJ. 2006;332(7532):25-9.

5. Goadsby PJ. The ‘Act when Mild’ (AwM) study: a step forward in our understanding of early treatment in migraine when is still mild increases the efficacy of sumatriptan. Cephalalgia. 2004;24(11):925-33.

6. Graham JR, Wolff HG. Mechanisms of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatr. 1938;39:737-63.

7. Prusiński A. Migrena – rozpoznanie i leczenie. Przewodnik Lekarski. 2008;2:21-31.

8. Steiner T. Paemeliere K. i wsp. European Principles of Management of Common Headache Disorders in Primary Care. J Headache Pain. 2007;8 (Suppl 1).

9. Stępień A. Od patofizjologii do nowoczesnej terapii migreny – aktualny stan badań nad migreną. Terapia. 2010;11-12 (249):73-77.

10. Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J. Epidemiology of headache in Europe. European Journal of Neurology. 2006;4:333-345.

11. Domitrz I, Kozubski W. Rekomendacje diagnostyczno terapeutyczne postępowania w migrenie. PPN. 2019;suppl. B(15):1-20.

12. Jastrzębski K. Tryptany w migrenowych bólach głowy – bilans korzyści i ryzyka. Aktualności Neurologiczne. 2017;17(2):104-114.

13. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. The AMPP Advisory Group Migraine prevalence, disease burden, and the need for preventive therapy. NEUROLOGY. 2007;68:343-349.

14. Aurora SK, Kori SH, Barrodale P, et al. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46:57-63.

15. Wysocka-Bąkowska MM. Nudności i wymioty wyzwaniem w terapii migreny. Leczenie doraźne migreny. Neurologia Praktyczna. 2015;2:47-56.

16. Bousser MG, D’Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Intern ed. 1993;234:211-216.

17. Headache Classification Subcommittee of the International Headache Society (IHS). The International Classification of Headache Disorders, 2nd ed.Cephalalgia. 2004;24(Suppl 1):1–160.

18. Dodick DW, Diener H-C. Triptans for Migraine. Unitec House, 2 Albert Place, London N3 1QB, UK: Future Medicine Ltd; 2012.

19. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012.

20. Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012.

21. Orr SL, Friedman BW, Christie S, et al. Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache J Head Face Pain. 2016;56:911-40.

22. Menshawy A, Ahmed H, Ismail A, et al. Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis. Neurol Sci. 2018;39:31-44.

23. Erlichson K, Waight Therapeutic applications for subcutaneous triptans in acute treatment of migraine J Curr. Med. Res. & Opinion Vol. 28,No 7.2012 ,1231-1238.

24. Ekbom K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose-comparison study. Acta Neurol Scand. 1993;88:63-9.

25. Bousser MG, D’Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Intern Med. 1993;234:211-16.

26. Salonen R, Saiers J. Sumatriptan jest skuteczny w leczeniu migreny menstruacyjnej: przegląd badań prospektywnych i analiz retrospektywnych. Cephalalgia. 1999;19:16-19.

27. Welch KM, Mathew NT, Stone P, et al. Tolerancja sumatryptanu: badania kliniczne i doświadczenia po wprowadzeniu na rynek. Cephalalgia. 2000;20:687-95.

28. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44:414-25.

29. Cady RK, Aurora SK, Brandes JL, et al. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache. 2011;51:1202-11.

30. Kilminster SG, Dowson AJ, Tepper SJ, et al. Reliability, validity, and clinical utility of the Migraine-ACT questionnaire. Headache. 2006;46:553-62.

31. Rothrock JF, Cady RK, Aurora SK, et al. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Curr Med Res Opin. 2011;27:2185-91.